IL13Rα2 + B7-H3 Dual-Target CAR-NK CAR-NK (Beijing Biotech)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameIL13Rα2 + B7-H3 Dual-Target CAR-NK CAR-NK (Beijing Biotech)

Drug Alias NameIL13Rα2 + CD276 Dual-Target CAR-NK (Beijing Biotech)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionAnti-CD276Anti-IL13RA2

TargetsCD276 antigenInterleukin-13 receptor subunit alpha-2

Therapy Area/IndicationsHigh-Grade GliomaGlioblastomaGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBeijing Biotech

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech

Inactive CompaniesN/A

Active IndicationsHigh-Grade GliomaGlioblastomaGlioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A